Goodrx Holdings, INC Form 4 insider transactions

Justin Fengler, See Remarks of GoodRx Holdings, Inc., received 190,204 shares of common stock on August 10, 2026.

Christopher A Mcginnis, See Remarks of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Wendy Lynn Barnes, See Remarks and a Director of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Thomas (Tc) Chan, Chief Accounting Officer of GoodRx Holdings, Inc., reported multiple transactions in common stock on July 15, 2026.

Director Agnes Rey-Giraud was granted 73,434 restricted stock units in GoodRx Holdings, Inc.

GoodRx Holdings, Inc. director Kelly J. Kennedy was granted 73,434 restricted stock units as part of standard equity compensation.

Director Douglas Hirsch was granted 73,434 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.

GoodRx Holdings, Inc. director Ronald E. Bruehlman was granted 73,434 deferred stock units as part of his annual compensation.

Director Trevor Bezdek acquired 73,434 restricted stock units in GoodRx Holdings, Inc. as part of an equity compensation grant.

Director Scott Wagner was granted 73,434 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.

GoodRx Chief Accounting Officer Thomas Chan acquired Class A common stock through RSU vesting and subsequently sold a portion to cover tax obligations.

Director Trevor Bezdek was granted 110,294 restricted stock units as part of his compensation package with GoodRx Holdings, Inc.

Director Douglas Hirsch was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.

Director Ronald E. Bruehlman was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.

GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan acquired 5,575 shares through RSU vesting and disposed of 2,838 shares to cover tax obligations.

GoodRx Holdings CFO Christopher A. McGinnis acquired 44,779 shares through RSU vesting and disposed of 19,726 shares to cover tax obligations.

GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan was granted 54,494 restricted stock units on May 11, 2026.

GoodRx Holdings CFO Christopher McGinnis acquired 36,987 shares via RSU vesting and disposed of 10,745 shares for tax obligations.

GoodRx CEO Wendy Barnes acquired 277,288 shares through RSU vesting and disposed of 120,456 shares to cover tax obligations.

GoodRx Holdings Director Agnes Rey-Giraud exercised stock options and transferred shares to a family trust, adjusting her beneficial ownership.

GoodRx Holdings, Inc. Chief Financial Officer Christopher A McGinnis was granted 443,852 restricted stock units, vesting quarterly over three years.

GoodRx Holdings, Inc. reported that its Chief Accounting Officer, Romin Nabiey, was granted 108,189 restricted stock units.

GoodRx Holdings, Inc. CEO and President Wendy Lynn Barnes was granted 1,331,557 restricted stock units, vesting quarterly over three years.

GoodRx Chief Accounting Officer Romin Nabiey reported the future vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

GoodRx Holdings, Inc. Director Scott Wagner acquired 31,394 shares of Class A Common Stock following the vesting of deferred stock units on January 21, 2026.

GoodRx Director and Officer Wendy Lynn Barnes reported the exercise of restricted stock units and subsequent tax-related sales of Class A Common Stock on January 15, 2026.

GoodRx Holdings, Inc. Director Douglas Joseph Hirsch reported the acquisition of 10,950 deferred stock units under a Rule 10b5-1 plan.

GoodRx Holdings, Inc. Director Ronald E Bruehlman acquired 18,251 deferred stock units, increasing his direct beneficial ownership to 129,276 shares.

GoodRx Holdings, Inc. Director Kelly J. Kennedy converted 23,149 restricted stock units into Class A common stock, increasing her direct beneficial ownership.

GoodRx's Chief Accounting Officer, Romin Nabiey, reported planned future transactions involving the exercise of restricted stock units and subsequent sale of shares for tax withholding.